Literature DB >> 16270633

High dose dexamethasone increases circulating P-selectin and von Willebrand factor levels in healthy men.

Bernd Jilma1, Tuende Cvitko, Astrid Winter-Fabry, Karin Petroczi, Peter Quehenberger, Andrew D Blann.   

Abstract

Although glucocorticoids are widely used in a number of inflammatory disorders associated with endothelial and platelet activation, their effect on the endothelium and platelets in humans remain poorly defined. Hence,we measured changes of a specific endothelial cell marker (von Willebrand factor [vWF]) and of a platelet marker (soluble P-selectin) by infusing therapeutic doses of dexamethasone (0.04 mg/kg and 1.0 mg/kg b.i.d on two days) or placebo into nine healthy men. Venous citrated plasma was obtained before infusion, and at 24 and 48 h. Compared to baseline levels, we found increased levels of vWF at both time points at the higher dose (p=0.011). Plasma levels of sP-selectin rose at 48 h after the high dose (p=0.017). Human umbilical endothelial cells were cultured in the presence or absence of dexamethasone (0, 0.01, 1 microM), to determine the possible mechanism for the increase in vWF. The vWF-mRNA levels as quantified by RT-PCR increased 2-fold (p<0.05), and the vWF-concentrations in cell lysates increased by 38% (p<0.05), whereas the vWF-concentrations in the supernatants were unaffected. In summary, high dose DEXA increases sP-selectin and vWF. The probable underlying mechanism for the latter was a DEXA induced up-regulation of vWF-mRNA transcription. Together, this indicates that high dose glucocorticoids may enhance haemostasis, which could be beneficial under certain conditions, but which may also contribute to adverse vascular events by increasing platelet activation and vWF dependent thrombosis.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 16270633     DOI: 10.1160/TH04-10-0652

Source DB:  PubMed          Journal:  Thromb Haemost        ISSN: 0340-6245            Impact factor:   5.249


  23 in total

1.  Ischemic heart disease associated with bortezomib treatment combined with dexamethasone in a patient with multiple myeloma.

Authors:  Hiroyuki Takamatsu; Takeshi Yamashita; Takeharu Kotani; Aiko Sawazaki; Hirokazu Okumura; Shinji Nakao
Journal:  Int J Hematol       Date:  2010-05-11       Impact factor: 2.490

Review 2.  Nonclinical aspects of venous thrombosis in pregnancy.

Authors:  Evi Struble; Wafa Harrouk; Albert DeFelice; Belay Tesfamariam
Journal:  Birth Defects Res C Embryo Today       Date:  2015-09-25

3.  Autoimmune diseases and venous thromboembolism: a review of the literature.

Authors:  Bengt Zöller; Xinjun Li; Jan Sundquist; Kristina Sundquist
Journal:  Am J Cardiovasc Dis       Date:  2012-07-25

4.  A predictive value of von Willebrand factor for early response to Bevacizumab therapy in recurrent glioma.

Authors:  Andrea Pace; Chiara Mandoj; Anna Antenucci; Veronica Villani; Isabella Sperduti; Beatrice Casini; Mariantonia Carosi; Alessandra Fabi; Antonello Vidiri; Tatiana Koudriavtseva; Laura Conti
Journal:  J Neurooncol       Date:  2018-03-28       Impact factor: 4.130

5.  Relation of morning serum cortisol to prothrombotic activity in women with stable coronary artery disease.

Authors:  Roland von Känel; Brent T Mausbach; Brigitte M Kudielka; Kristina Orth-Gomér
Journal:  J Thromb Thrombolysis       Date:  2007-06-12       Impact factor: 2.300

6.  Massive thoracoabdominal aortic thrombosis in a patient with iatrogenic Cushing syndrome.

Authors:  Dong Hun Kim; Dong-Hyun Choi; Young-Min Lee; Joon Tae Kang; Seung Seok Chae; Bo-Bae Kim; Young-Jae Ki; Jin Hwa Kim; Joong-Wha Chung; Young-Youp Koh
Journal:  Korean J Radiol       Date:  2014-09-12       Impact factor: 3.500

7.  Linkage analysis identifies a locus for plasma von Willebrand factor undetected by genome-wide association.

Authors:  Karl C Desch; Ayse B Ozel; David Siemieniak; Yossi Kalish; Jordan A Shavit; Courtney D Thornburg; Anjali A Sharathkumar; Caitlin P McHugh; Cathy C Laurie; Andrew Crenshaw; Daniel B Mirel; Yoonhee Kim; Cheryl D Cropp; Anne M Molloy; Peadar N Kirke; Joan E Bailey-Wilson; Alexander F Wilson; James L Mills; John M Scott; Lawrence C Brody; Jun Z Li; David Ginsburg
Journal:  Proc Natl Acad Sci U S A       Date:  2012-12-24       Impact factor: 11.205

Review 8.  Drug-induced thrombosis: an update.

Authors:  Yuval Ramot; Abraham Nyska; Galia Spectre
Journal:  Drug Saf       Date:  2013-08       Impact factor: 5.606

9.  Genetic associations with thalidomide mediated venous thrombotic events in myeloma identified using targeted genotyping.

Authors:  David C Johnson; Sophie Corthals; Christine Ramos; Antje Hoering; Kim Cocks; Nicholas J Dickens; Jeff Haessler; Harmut Goldschmidt; J Anthony Child; Sue E Bell; Graham Jackson; Dalsu Baris; S Vincent Rajkumar; Faith E Davies; Brian G M Durie; John Crowley; Pieter Sonneveld; Brian Van Ness; Gareth J Morgan
Journal:  Blood       Date:  2008-09-19       Impact factor: 22.113

10.  Risk of subsequent ischemic and hemorrhagic stroke in patients hospitalized for immune-mediated diseases: a nationwide follow-up study from Sweden.

Authors:  Bengt Zöller; Xinjun Li; Jan Sundquist; Kristina Sundquist
Journal:  BMC Neurol       Date:  2012-06-18       Impact factor: 2.474

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.